

SEQUENCE LISTING

<110> ProChon Biotech Ltd.
Golembo, Myriam
Yayon, Avner

<120> METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS

<130> PRO/011/US

<140> US

<141> 2003-09-15

<150> US 60/276,939

<151> 2001-02-20

<150> IL 142118

<151> 2001-02-20

<150> PCT/IL02/00229

<151> 2002-02-20

<160> 71

<170> PatentIn version 3.1

<210> 1

<211> 22

<212> PRT

<213> Homo sapiens

<300>

<308> P23582

<309> 2001-10-16

<313> (105)..(126)

<400> 1

Gly	Leu	Ser	Lys	Gly	Cys	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ser
1				5					10					15	

Met	Ser	Gly	Leu	Gly	Cys
			20		

<210> 2

<211> 17

<212> PRT

<213> Homo sapiens

<300>

<308> P23582

<309> 2001-10-16

<313> (110)..(126)

<400> 2

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
 1 5 10 15

Cys

<210> 3
 <211> 29
 <212> PRT
 <213> Homo sapiens

<300>
 <308> P01161
 <309> 2001-10-16
 <313> (123)..(150)

<400> 3

Pro Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile
 1 5 10 15

Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 20 25

<210> 4
 <211> 32
 <212> PRT
 <213> Homo sapiens

<300>
 <308> P16860
 <309> 2001-10-16
 <313> (103)..(134)

<400> 4

Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp
 1 5 10 15

Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His
 20 25 30

<210> 5
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> peptide variant

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> X at position 4 is defined as Xaa in the specification and is either Leu (L), Ile (I) or Val (V)

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> X at position 5 is defined as Xbb in the description and is either Lys (K), Leu (L) or Met (M)

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> X at position 6 is defined as Xcc in the description and is either Leu (L), Ile (I), Ala (A) or Val (V)

<220>
 <221> MISC_FEATURE
 <222> (11)..(11)
 <223> X at position 11 is defined as Xdd in the description and is either Ser (S), Ala (A), Gly (G), Thr (T) or Asn (N)

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> X at position 12 is defined as Xee in the description and is either Met (M), Ala (A), Lys (K), Trp (W).

<220>
 <221> MISC_FEATURE
 <222> (14)..(14)
 <223> X at position 14 is defined as Xff in the description and is either Gly (G), Lys (K), Ala (A) or Leu (L).

<220>
 <221> MISC_FEATURE
 <222> (15)..(15)
 <223> X at position 15 is defined as Xgg in the specification and is either Leu (L) or Met (M).

<400> 5

Cys	Phe	Gly	Xaa	Xaa	Xaa	Asp	Arg	Ile	Gly	Xaa	Xaa	Ser	Xaa	Xaa	Gly
1				5					10					15	

Cys

<210> 6
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 6

Cys Ala Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 7
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 7

Cys Phe Gly Leu Lys Leu Ala Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 8

Cys Phe Gly Leu Lys Leu Asp Ala Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 9

<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 9

Cys Phe Gly Leu Lys Leu Asp Arg Ala Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 10

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Ala Ser Gly Leu Gly
1 5 10 15

Cys

<210> 11
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 11

Cys His Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Cys
1 5 10 15

<210> 12
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 12

Cys	His	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ser	Met	Ala	Cys
1				5					10					15

<210> 13

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 13

Cys	His	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ala	Gln	Ser	Cys
1				5					10					15

<210> 14

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 14

Cys	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ser	Met	Ser	Cys
1				5					10				

<210> 15

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 15

Cys	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ala	Gln	Ser	Cys
1				5					10				

<210> 16

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 16

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Cys
1 5 10

<210> 17

<211> 13

<212> PRT

<213> Homo sapiens

<400> 17

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ala Met Cys
1 5 10

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 18

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Gln Cys
1 5 10

<210> 19

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 19

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ala Gln Cys
1 5 10

<210> 20

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 20

Cys His Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Cys
1 5 10

<210> 21
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 21

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Cys
1 5 10

<210> 22
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 22

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Cys
1 5 10

<210> 23
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 23

Cys His Phe Gly Leu Lys Leu Asp Arg Ile Cys
1 5 10

<210> 24
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 24

Cys Ala Gly Leu Lys Leu Ala Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 25
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 25

Cys Ala Gly Leu Lys Leu Asp Arg Ile Gly Ser Ala Ser Gly Leu Gly
1 5 10 15

Cys

<210> 26
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 26

Cys Phe Gly Leu Lys Leu Ala Arg Ile Gly Ser Ala Ser Gly Leu Gly
1 5 10 15

Cys

<210> 27
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 27

Cys Ala Gly Leu Lys Leu Ala Arg Ile Gly Ser Ala Ser Gly Leu Gly
1 5 10 15

Cys

<210> 28
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 28

Cys Ile Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 29
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 29

Cys Leu Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 30
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 30

Cys Met Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 31
<211> 17

<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 31

Cys Trp Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 32
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 32

Cys Val Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 33
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 33

Cys His Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence

<220>

<223> peptide variant

<400> 34

Cys Thr Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 35

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 35

Cys Phe Gly Leu Lys Leu Glu Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 36

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 36

Cys Phe Gly Leu Lys Leu Gln Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 37

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 37

Cys Phe Gly Leu Lys Leu Asn Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 38

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 38

Cys Phe Gly Leu Lys Leu Ile Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 39

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 39

Cys Phe Gly Leu Lys Leu Met Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 40

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> peptide variant

<400> 40

Cys Phe Gly Ala Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly

1 5 10 15

Cys

<210> 41
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 41

Cys Phe Gly Ile Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 42
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 42

Cys Phe Gly Val Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 43
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 43

Cys Phe Gly Leu Leu Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 44
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 44

Cys Phe Gly Leu Met Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 45
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 45

Cys Phe Gly Leu Lys Ala Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 46
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 46

Cys Phe Gly Leu Lys Ile Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 47
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 47

Cys Phe Gly Leu Lys Val Asp Arg Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 48
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 48

Cys Phe Gly Leu Lys Leu Asp His Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 49
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 49

Cys Phe Gly Leu Lys Leu Asp Lys Ile Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 50
<211> 17

<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 50

Cys	Phe	Gly	Leu	Lys	Leu	Asp	Gln	Ile	Gly	Ser	Met	Ser	Gly	Leu	Gly
1				5					10					15	

Cys

<210> 51
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 51

Cys	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Leu	Gly	Ser	Met	Ser	Gly	Leu	Gly
1				5					10					15	

Cys

<210> 52
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 52

Cys	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Val	Gly	Ser	Met	Ser	Gly	Leu	Gly
1				5					10					15	

Cys

<210> 53
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 53

Cys Phe Gly Leu Lys Leu Asp Arg Thr Gly Ser Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 54
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 54

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ala Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 55
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 55

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Gly Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 56
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 56

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Thr Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 57
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 57

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Asn Met Ser Gly Leu Gly
1 5 10 15

Cys

<210> 58
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 58

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Ala Leu Gly
1 5 10 15

Cys

<210> 59
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 59

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Leu Leu Gly

Cys

<210> 63
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 63

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Ala Gly
1 5 10 15

Cys

<210> 64
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 64

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Gly Gly
1 5 10 15

Cys

<210> 65
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 65

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Trp Ser Gly Leu Gly
1 5 10 15

Cys

<210> 66
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 66

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser His Ser Gly Leu Gly
1 5 10 15

Cys

<210> 67
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 67

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Lys Ser Gly Leu Gly
1 5 10 15

Cys

<210> 68
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 68

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Ser Ser Gly Leu Gly
1 5 10 15

Cys

<210> 69
<211> 17

<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 69

Cys	Phe	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ser	Gly	Ser	Gly	Leu	Gly
1				5					10					15	

Cys

<210> 70
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 70

Cys	His	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ser	Ala	Ser	Gly	Leu	Gly
1				5					10					15	

Cys

<210> 71
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide variant

<400> 71

Cys	Thr	Gly	Leu	Lys	Leu	Asp	Arg	Ile	Gly	Ser	Ala	Ser	Gly	Leu	Gly
1				5					10					15	

Cys